BioNTech Shareholders to Vote on Pivotal Restructuring Measures

BioNTech's virtual AGM features critical votes on a new tax structure, capital authorization, and board expansion as the company navigates a post-COVID revenue decline and funds its oncology pipeline.

On May 15, 2026, BioNTech SE will convene its Annual General Meeting in a virtual format, with no physical attendance by shareholders. The agenda is notably packed, highlighting the scale of the company's ongoing strategic transformation, which includes proposals for a new tax structure, an expanded supervisory board, and fresh capital authorization.

Financial Pressures and Strategic Shift

This corporate overhaul is unfolding against a backdrop of significant financial headwinds. Following modest revenue growth of four percent in 2025, BioNTech anticipates a decline of approximately 25 percent for 2026, projecting sales between €2.0 billion and €2.3 billion. The COVID-19 vaccine business continues to contract. A post-marketing study mandated by the FDA, conducted jointly with Pfizer, has been suspended due to insufficient patient recruitment, not safety concerns. This development comes at a sensitive time, as U.S. regulators are set to decide on vaccine strain recommendations for the fall season in May.

The company's long-term growth strategy is firmly anchored in its oncology pipeline. BioNTech aims to have 15 Phase 3 trials underway and to present data from seven late-stage development programs by the end of 2026. However, management does not expect commercial revenue from this pipeline during the 2026 fiscal year. A substantial liquidity reserve of about €17.2 billion at the end of 2025 provides the financial runway necessary to fund this transition.

Key Proposals for Shareholder Approval

Central to the meeting's agenda is a vote on a domination and profit transfer agreement with the subsidiary BioNTech Discovery GmbH. The objective is to establish a group for corporate and trade tax purposes, enabling the offsetting of profits at the subsidiary level against losses at the parent company. Given the parent company's net loss of €1.14 billion for the 2025 financial year, this move carries substantive financial implications.

Concurrently, shareholders will be asked to replace the existing authorized capital with a new "Authorized Capital 2026." This would allow for capital increases of up to €129.5 million, equivalent to 50 percent of the current share capital. Furthermore, a proposal seeks to enlarge the supervisory board from six to eight members. The planned expansion includes adding two new specialists with expertise in oncology and clinical development.

The upcoming shareholder vote will serve as a critical indicator of investor confidence in management's comprehensive restructuring plan, spanning from tax optimization to governance changes.